Full-Time

Director Technical Operations

Updated on 8/1/2026

Travere Therapeutics

Travere Therapeutics

501-1,000 employees

Develops and commercializes rare-disease therapies

Compensation Overview

$189k - $246k/yr

+ Short-term incentive + Company stock

San Diego, CA, USA

Hybrid

Face-to-face work in San Diego is required; the role is not 100% remote and includes 10–20% domestic and international travel.

Category
Biology & Biotech (1)
Required Skills
Six Sigma
GMP
Biochemistry

Get referred to Travere Therapeutics

See people who can refer or advise you

Requirements
  • A bachelor's degree in Life Sciences, Chemistry, Pharmaceutical Sciences, Biochemistry, Chemical Engineering, or a related discipline is required; an equivalent combination of education and applicable job experience may be considered.
  • At least 10 years of relevant experience, depending on degree, in small molecule active pharmaceutical ingredient development and manufacturing, with emphasis on late-phase clinical development, scale-up, and commercialization.
  • Expert knowledge and extensive Chemistry, Manufacturing, and Controls experience advancing small molecule active pharmaceutical ingredients from process development through process characterization, process performance qualification, commercialization, and technology transfers in support of solid oral dosage form programs.
  • Extensive experience managing global contract development and manufacturing organizations, third-party manufacturers, and testing laboratories.
  • Broad knowledge and experience with phase-appropriate current good manufacturing practice requirements and applicable United States, European Union, and International Council for Harmonisation guidelines.
  • Demonstrated ability to prepare and review Chemistry, Manufacturing, and Controls sections of regulatory filings, including Investigational New Drugs, Investigational Medicinal Product Dossiers, and New Drug Applications.
  • Ability to adapt to modifications and changes to project plans, implementing new strategies and tactics as needed.
  • Strong interpersonal, organizational, verbal communication, written communication, decision-making, collaboration, and attention-to-detail skills.
  • Ability to travel 10–20% domestically and internationally.
  • Ability to perform face-to-face work with colleagues and/or work onsite in San Diego.
Responsibilities
  • Provide technical oversight of active pharmaceutical ingredient production, scale-up, process characterization, and process performance qualification for a small molecule solid oral drug product manufactured at Travere contract development and manufacturing organizations.
  • Review and approve manufacturing-related documentation, including change notifications, batch records, process development, technology transfer, process characterization, and validation protocols and reports.
  • Verify the suitability, qualification, and validation status of processes at contract development and manufacturing organizations and other external laboratories.
  • Provide technical support for current good manufacturing practice quality management systems, including deviations, investigations, corrective and preventive actions, change controls, regulatory submissions, and facility inspections.
  • Collaborate with internal and external project teams to support Chemistry, Manufacturing, and Controls development, clinical supply, commercialization, and lifecycle management of small molecule drug products.
  • Author and review technical documents and regulatory submission content, including Investigational New Drugs, Investigational Medicinal Product Dossiers, and New Drug Applications.
  • Maintain current knowledge of United States and European Union current good manufacturing practice requirements, International Council for Harmonisation guidelines, and other regulatory expectations applicable to pharmaceutical development and manufacturing.
  • Review project scope, timelines, and deliverables to ensure contract development and manufacturing organization activities meet contractual obligations, quality standards, and program objectives.
Desired Qualifications
  • An M.S., Ph.D., or other advanced degree in a related discipline is preferred.
  • Strong professional experience in a similar pharmaceutical-industry role, preferably in small molecule development and manufacturing for solid oral dosage forms.
  • A successful record of creating and managing complex project plans, timelines, budgets, and risk-mitigation strategies.
  • Six Sigma and statistical knowledge.

Travere Therapeutics develops and commercializes therapies for rare diseases, especially kidney and metabolic disorders. It has commercial products Thiola and Thiola EC for cystinuria and Chenodal for gallstones, with a pipeline that includes sparsentan for focal segmental glomerulosclerosis and IgA nephropathy. The company generates revenue from the sale of its products and supports patients through a dedicated patient assistance program. Its approach centers on identifying and delivering treatments for rare diseases, combining commercialization with ongoing drug development.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2008

Get referred to Travere Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FILSPARI's FDA approvals support near-term revenue growth and commercial leverage.
  • Pegtibatinase in Phase 3 offers a new asset in classical homocystinuria.
  • R&D leadership transition to Jula Inrig preserves clinical and regulatory continuity.

What critics are saying

  • FILSPARI faces generic entry and patent-challenge pressure over the next two years.
  • Civorebrutinib remains early-stage, so trial failures would erase deal value.
  • Commercial execution in IgAN and FSGS depends on reimbursement, uptake, and manufacturing reliability.

What makes Travere Therapeutics unique

  • Travere focuses on rare kidney and metabolic diseases with commercial and pipeline assets.
  • FILSPARI is approved for IgAN and FSGS, strengthening its nephrology franchise.
  • The 2026 civorebrutinib deal expands Travere into immune-mediated kidney diseases.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Wellness Program

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

6%

2 year growth

6%
Yahoo Finance
Apr 14th, 2026
Travere's FILSPARI receives FDA approval for FSGS, earns Ligand 9% royalty on sales

Ligand Pharmaceuticals' partner Travere Therapeutics has received FDA approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS) in adult and paediatric patients aged eight and older without nephrotic syndrome. FILSPARI becomes the first and only FDA-approved medicine for FSGS, a rare kidney disorder and leading cause of kidney failure. The approval expands FILSPARI beyond IgA nephropathy, where it is already the most commonly prescribed FDA-approved medicine. Ligand is entitled to a 9% royalty on worldwide net sales. Travere estimates the addressable US population exceeds 30,000 individuals with FSGS without nephrotic syndrome. In the Phase 3 DUPLEX Study, FILSPARI demonstrated a statistically significant 48% reduction in proteinuria compared to 27% for irbesartan in patients without nephrotic syndrome.

Yahoo Finance
Apr 13th, 2026
FDA fully approves FILSPARI for FSGS, first treatment for rare kidney disease affecting 30K US patients

Travere Therapeutics announced that the FDA has granted full approval for FILSPARI (sparsentan) to reduce proteinuria in adults and children aged 8 years and older with focal segmental glomerulosclerosis (FSGS) who do not have nephrotic syndrome. FILSPARI is the first and only FDA-approved medicine for FSGS. The approval expands FILSPARI's addressable population to more than 100,000 patients in the US, including over 30,000 with FSGS. The drug is already the most commonly prescribed FDA-approved medicine for IgA nephropathy. In the Phase 3 DUPLEX Study, FILSPARI demonstrated a statistically significant 46% reduction in proteinuria compared to 30% for irbesartan. In patients without nephrotic syndrome specifically, the reduction was 48% versus 27%. The medicine was generally well tolerated across adult and paediatric patients.

The Motley Fool
Jan 25th, 2026
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? | The Motley Fool

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

The Motley Fool
Jan 24th, 2026
Palisades Investment buys $5.3M stake in Travere Therapeutics as shares surge 51%

Palisades Investment Partners initiated a new position in Travere Therapeutics worth $5.26 million, acquiring 137,768 shares in the fourth quarter of 2025, according to an SEC filing. The stake represents 1.99% of the fund's $264.72 million in reportable US equity assets. Travere Therapeutics, a biotechnology company specialising in rare disease therapies, has seen its shares rise 50.89% over the past year to $27.87. The company's revenue surged to $164.9 million in the third quarter, driven by a 155% year-over-year increase in sales of its FILSPARI drug to $90.9 million. The timing of Palisades' investment coincided with FDA review of FILSPARI for potential expanded approval in focal segmental glomerulosclerosis treatments, suggesting confidence in the company's growth prospects.

GlobeNewswire
Jan 13th, 2026
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

TVTX ALERT: investigation launched into Travere Therapeutics, Inc., RGRD law attorneys encourage investors and potential witnesses to contact law Firm. SAN DIEGO, Jan. 13, 2026 (GLOBE NEWSWIRE) - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. THE COMPANY: Travere is a biopharmaceutical company that develops therapies for people living with rare kidney and metabolic diseases in the United States. THE INVESTIGATION: Robbins Geller is investigating whether Travere and certain of its top executives made materially false and/or misleading statements and/or omitted material information regarding Travere's business and operations. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases - more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever - $7.2 billion - in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.